Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNBNASDAQ:JANXNASDAQ:MESOOTCMKTS:NWBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89bio$9.62-4.2%$7.87$4.16▼$11.84$1.40B1.31.49 million shs4.55 million shsJANXJanux Therapeutics$25.56+0.4%$26.97$22.48▼$71.71$1.51B2.96869,303 shs545,583 shsMESOMesoblast$12.16+2.4%$11.18$5.78▼$22.00$1.55B2.41272,223 shs214,686 shsNWBONorthwest Biotherapeutics$0.26-0.8%$0.27$0.17▼$0.50$377.18M-1.093.65 million shs2.14 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89bio-2.33%-0.20%+23.80%+22.74%+15.67%JANXJanux Therapeutics-2.97%+1.31%-2.30%-18.79%-39.44%MESOMesoblast-6.61%+3.58%+4.58%-10.62%+62.83%NWBONorthwest Biotherapeutics-3.68%-1.06%-8.93%+7.82%-41.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89bio2.7372 of 5 stars3.53.00.00.03.60.80.6JANXJanux Therapeutics2.4195 of 5 stars3.52.00.00.02.92.50.0MESOMesoblast2.3493 of 5 stars3.53.00.00.02.20.80.6NWBONorthwest Biotherapeutics0.1102 of 5 stars0.02.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89bio 3.00Buy$26.43174.73% UpsideJANXJanux Therapeutics 3.09Buy$95.25272.65% UpsideMESOMesoblast 3.00Buy$18.0048.03% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWBO, JANX, ETNB, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/31/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89bioN/AN/AN/AN/A$5.75 per shareN/AJANXJanux Therapeutics$9.34M162.01N/AN/A$7.46 per share3.43MESOMesoblast$5.67M274.04N/AN/A$4.21 per share2.89NWBONorthwest Biotherapeutics$1.93M195.43N/AN/A($0.06) per share-4.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%8/4/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%8/6/2025 (Estimated)MESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)NWBONorthwest Biotherapeutics-$62.60M-$0.07N/A∞N/A-4,666.29%N/A-261.36%8/7/2025 (Estimated)Latest NWBO, JANX, ETNB, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.38 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A3/31/2025Q4 2024NWBONorthwest BiotherapeuticsN/A-$0.02N/A-$0.02N/A$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89bioN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89bio0.0911.6611.66JANXJanux TherapeuticsN/A38.8038.80MESOMesoblast0.211.181.18NWBONorthwest BiotherapeuticsN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89bioN/AJANXJanux Therapeutics75.39%MESOMesoblast1.43%NWBONorthwest Biotherapeutics0.04%Insider OwnershipCompanyInsider OwnershipETNB89bio2.60%JANXJanux Therapeutics8.10%MESOMesoblast18.80%NWBONorthwest Biotherapeutics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89bio40145.98 million103.15 millionOptionableJANXJanux Therapeutics3059.18 million37.05 millionOptionableMESOMesoblast80127.78 million103.17 millionOptionableNWBONorthwest Biotherapeutics201.45 billion1.24 billionNot OptionableNWBO, JANX, ETNB, and MESO HeadlinesRecent News About These CompaniesNorthwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 11 at 12:49 PM | prnewswire.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average - Time to Sell?June 7, 2025 | marketbeat.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?May 31, 2025 | marketbeat.comNorthwest Biotherapeutics: A Spike On Their Expected Imminent ApprovalApril 22, 2025 | seekingalpha.comCitadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)March 29, 2025 | news.bloomberglaw.comInvestors Watching Two Small-Caps for News on Potential Major Advancements in Cancer TreatmentsJanuary 13, 2025 | msn.comNorthwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional FinancingDecember 26, 2024 | prnewswire.comNorthwest Biotherapeutics: All Is Not Well With This OneDecember 14, 2024 | seekingalpha.comBehind the Bell: Arcutis BiotherapeuticsNovember 5, 2024 | nasdaq.comNorthwest Registered Agent Review 2024: Features, Pricing & MoreOctober 24, 2024 | forbes.com0K95.IL,0P0000AFQ5,0 (0K95.IL)September 14, 2024 | nz.finance.yahoo.comTraders News Digs into the Biotech Space and Releases New Feature ProfileAugust 15, 2024 | br.advfn.comNorthwest Biotherapeutics addresses rumors and market activityAugust 4, 2024 | uk.investing.comNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth OpportunitiesJuly 3, 2024 | prnewswire.comNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual PropertyJune 17, 2024 | prnewswire.comNorthwest Biotherapeutics Inc (NWBO) Dividend HistoryMay 25, 2024 | nasdaq.comNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsMarch 21, 2024 | prnewswire.com‘Spoofing’ case might draw back curtain on high-speed trading firmsMarch 2, 2024 | ft.comNorthwest Biotherapeutics, Inc. (NWBO)February 29, 2024 | uk.finance.yahoo.comNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest ReportFebruary 23, 2024 | benzinga.comNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationFebruary 7, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWBO, JANX, ETNB, and MESO Company Descriptions89bio NASDAQ:ETNB$9.62 -0.42 (-4.18%) As of 04:00 PM Eastern89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Janux Therapeutics NASDAQ:JANX$25.56 +0.10 (+0.39%) As of 04:00 PM EasternJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Mesoblast NASDAQ:MESO$12.16 +0.29 (+2.44%) As of 04:00 PM EasternMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Northwest Biotherapeutics OTCMKTS:NWBO$0.26 0.00 (-0.76%) As of 03:59 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
